Loading...
•
Sep 30, 2020
Adaptimmune Q3 2020 Earnings Report
Reported financial results and provided a business update for the third quarter ended September 30, 2020.
Key Takeaways
Adaptimmune reported their Q3 financial results and business update, highlighting upcoming data presentations at SITC and CTOS, and confirming financial guidance into 2022. Recruitment into clinical trials has been steadily recovering following the first wave of COVID-19.
Data from Phase 1 Trial with ADP-A2AFP in liver cancer presented at ILC confirm safety profile and demonstrate potential benefit for patients.
Safety and response data from dose escalation cohorts of the SURPASS trial to be presented at SITC.
Durability of response data from patients with synovial sarcoma from the Phase 1 ADP-A2M4 trial to be presented at CTOS.
Virtual Investor Day planned for November 20, 2020.
Forward Guidance
The Company believes that its existing cash, cash equivalents and marketable securities will fund the Company’s current operations into 2022.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...